A Phase 2 interventional study of Evolocumab and Placebo in Hypercholesterolemia, Familial, sponsored by Amgen. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-15.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH).
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
This study's enrollment of 168 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Browse Hyperlipoproteinemia Type II studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Placebo
Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
d by subcutaneous injection
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Absolute Change From Baseline in LDL-C at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12
Time frame: Baseline and Week 12
Men and women 18 to to 75 years of age, with a diagnosis of heterozygous familial hypercholesterolemia, fasting low-density lipoprotein cholesterol (LDL-C) of ≥ 100 mg/dL, and fasting triglycerides ≤ 400 mg/dL were eligible for this study. The first patient was enrolled on 02 August 2011 and the last patient was enrolled on 20 February 2012.
| Milestone | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Started | 56 | 56 | 56 |
| Received treatment | 56 | 55 | 56 |
| Completed | 56 | 55 | 56 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
LDL-C was measured using ultracentrifugation.
| percent change | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | 1.12 ± 2.88 | -42.70 ± 2.93 | -55.24 ± 2.88 |
LDL-C was measured using ultracentrifugation.
| mg/dL | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Absolute Change From Baseline in LDL-C at Week 12 | 4.2 ± 5.2 | -61.3 ± 5.4 | -80.5 ± 5.2 |
| percent change | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 12 | 2.48 ± 2.80 | -39.31 ± 2.86 | -50.98 ± 2.80 |
| percent change | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | 2.86 ± 2.61 | -31.89 ± 2.66 | -43.34 ± 2.61 |
| percent change | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12 | 2.98 ± 2.73 | -33.69 ± 2.79 | -42.03 ± 2.73 |
| percent change | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12 | -4.10 ± 2.53 | -38.02 ± 2.58 | -48.74 ± 2.53 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/56 (0%) | 24/56 (42.9%) |
| Evolocumab 350 mg | — | 0/55 (0%) | 22/55 (40%) |
| Evolocumab 420 mg | — | 2/56 (3.6%) | 19/56 (33.9%) |
| Event | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/56 | 0/55 | 1/56 |
| AppendicitisInfections and infestations | 0/56 | 0/55 | 1/56 |
| Postoperative wound infectionInfections and infestations | 0/56 | 0/55 | 1/56 |
| Event | Placebo | Evolocumab 350 mg | Evolocumab 420 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/56 | 7/55 | 7/56 |
| InfluenzaInfections and infestations | 6/56 | 1/55 | 4/56 |
| Injection site painGeneral disorders | 1/56 | 5/55 | 2/56 |
| HeadacheNervous system disorders | 5/56 | 3/55 | 3/56 |
| SinusitisInfections and infestations | 1/56 | 3/55 | 1/56 |
| Upper respiratory tract infectionInfections and infestations | 0/56 | 3/55 | 2/56 |
| DiarrhoeaGastrointestinal disorders | 3/56 | 0/55 | 2/56 |
| NauseaGastrointestinal disorders | 3/56 | 1/55 | 1/56 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/56 | 0/55 | 0/56 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/56 | 1/55 | 0/56 |
Full analysis set (all randomized participants who received at least 1 dose of investigational product).
| Age, Continuous(years) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| Mean | 49.3 ± 11.3 | 47.6 ± 13.6 | 51.8 ± 13.0 | 49.6 ± 12.7 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| Female | 32 | 25 | 21 | 78 |
| Male | 24 | 30 | 35 | 89 |
| Race/Ethnicity, Customized(participants) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 2 |
| Not Hispanic or Latino | 54 | 55 | 56 | 165 |
| Race/Ethnicity, Customized(participants) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| Asian | 3 | 1 | 3 | 7 |
| Black or African American | 0 | 3 | 1 | 4 |
| White | 48 | 48 | 52 | 148 |
| Other | 4 | 3 | 0 | 7 |
| Mixed Race | 1 | 0 | 0 | 1 |
| Stratification Factor: LDL-C Level(participants) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| < 130 mg/dL | 19 | 17 | 19 | 55 |
| ≥ 130 mg/dL | 37 | 38 | 37 | 112 |
| Stratification Factor: Baseline Use Of Ezetimibe(participants) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| No | 20 | 19 | 20 | 59 |
| Yes | 36 | 36 | 36 | 108 |
| LDL-C Concentration(mg/dL) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| Mean | 160.8 ± 44.0 | 156.8 ± 46.1 | 149.5 ± 36.3 | 155.7 ± 42.3 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Placebo | Evolocumab 350 mg | Evolocumab 420 mg | Total |
|---|---|---|---|---|
| Mean | 182.7 ± 52.6 | 178.0 ± 51.7 | 171.0 ± 43.6 | 177.2 ± 49.4 |
3 further baseline measures are reported on the registry.
No study locations are listed for this record.
Ran from Aug 2011 to primary completion in May 2012, 9 months.
Results were first posted in Sep 2015, 3 years 4 months after primary completion. A results delay was requested in Apr 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab
Hyperlipoproteinemia Type II →